MovDisordV3, Main, Exploration, bibRecord, 005D11

Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

Identifieur interne : 005D11 ( Main/Exploration ); précédent : 005D10; suivant : 005D12

Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

Auteurs : Mark Forrest Gordon [États-Unis] ; Rolando Diaz-Olivo [États-Unis] ; Ann L. Hunt [États-Unis] ; Fahn [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1993.

RBID : ISTEX:4D6408861423607BD4C2335834D9A2AD0E49505A

Descripteurs français

Pascal (Inist)
- Chimiothérapie, Essai clinique, Homme, Milacémide, Myoclonie, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Acetamides (administration & dosage), Acetamides (therapeutic use), Administration, Oral, Adult, Aged, Basal Ganglia (drug effects), Basal Ganglia (physiopathology), Blood-Brain Barrier (drug effects), Chemotherapy, Clinical trial, Cortical‐basal ganglionic degeneration, Double-Blind Method, Female, Glycine, Glycine (therapeutic use), Human, Humans, Male, Middle Aged, Milacemide, Movement Disorders (classification), Movement Disorders (drug therapy), Movement Disorders (physiopathology), Myoclonus, Progressive supranuclear palsy, Stiff‐person syndrome, Striatonigral degeneration, Synaptic Transmission (drug effects), Treatment, Videotape Recording, X‐linked dystonia.
MESH :
- chemical , administration & dosage : Acetamides.
- chemical , therapeutic use : Acetamides, Glycine.
- classification : Movement Disorders.
- drug effects : Basal Ganglia, Blood-Brain Barrier, Synaptic Transmission.
- drug therapy : Movement Disorders.
- physiopathology : Basal Ganglia, Movement Disorders.
- Administration, Oral, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Videotape Recording.

Abstract

We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X‐linked dystonia with parkinsonism, painful legs and moving toes, and stiff‐person syndrome. Milacemide was initiated at a dose of 2,400 mg/ day, orally, and increased gradually to a maximum of 4,800 mg/ day. No clear‐cut observable improvement occurred. There were no serious adverse effects.

Url:

https://api.istex.fr/document/4D6408861423607BD4C2335834D9A2AD0E49505A/fulltext/pdf

DOI: 10.1002/mds.870080412

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders</title>
<author><name sortKey="Gordon, Mark Forrest" sort="Gordon, Mark Forrest" uniqKey="Gordon M" first="Mark Forrest" last="Gordon">Mark Forrest Gordon</name>
</author>
<author><name sortKey="Diaz Livo, Rolando" sort="Diaz Livo, Rolando" uniqKey="Diaz Livo R" first="Rolando" last="Diaz-Olivo">Rolando Diaz-Olivo</name>
</author>
<author><name sortKey="Hunt, Ann L" sort="Hunt, Ann L" uniqKey="Hunt A" first="Ann L." last="Hunt">Ann L. Hunt</name>
</author>
<author><name sortKey="Fahn" sort="Fahn" uniqKey="Fahn" last="Fahn">Fahn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4D6408861423607BD4C2335834D9A2AD0E49505A</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1002/mds.870080412</idno>
<idno type="url">https://api.istex.fr/document/4D6408861423607BD4C2335834D9A2AD0E49505A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003252</idno>
<idno type="wicri:Area/Istex/Curation">003252</idno>
<idno type="wicri:Area/Istex/Checkpoint">003F78</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Gordon M:therapeutic:trial:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8232358</idno>
<idno type="wicri:Area/PubMed/Corpus">004B83</idno>
<idno type="wicri:Area/PubMed/Curation">004B83</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004B85</idno>
<idno type="wicri:Area/Ncbi/Merge">004936</idno>
<idno type="wicri:Area/Ncbi/Curation">004936</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004936</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Gordon M:therapeutic:trial:of</idno>
<idno type="wicri:Area/Main/Merge">008F50</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:94-0143145</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003670</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003154</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003664</idno>
<idno type="wicri:doubleKey">0885-3185:1993:Gordon M:therapeutic:trial:of</idno>
<idno type="wicri:Area/Main/Merge">009084</idno>
<idno type="wicri:Area/Main/Curation">005D11</idno>
<idno type="wicri:Area/Main/Exploration">005D11</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders</title>
<author><name sortKey="Gordon, Mark Forrest" sort="Gordon, Mark Forrest" uniqKey="Gordon M" first="Mark Forrest" last="Gordon">Mark Forrest Gordon</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Neurology, The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Diaz Livo, Rolando" sort="Diaz Livo, Rolando" uniqKey="Diaz Livo R" first="Rolando" last="Diaz-Olivo">Rolando Diaz-Olivo</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Neurology, The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunt, Ann L" sort="Hunt, Ann L" uniqKey="Hunt A" first="Ann L." last="Hunt">Ann L. Hunt</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Neurology, The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fahn" sort="Fahn" uniqKey="Fahn" last="Fahn">Fahn</name>
<affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Department of Neurology, The Neurological Institute, Columbia‐Presbyterian Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1993">1993</date>
<biblScope unit="vol">8</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="484">484</biblScope>
<biblScope unit="page" to="488">488</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4D6408861423607BD4C2335834D9A2AD0E49505A</idno>
<idno type="DOI">10.1002/mds.870080412</idno>
<idno type="ArticleID">MDS870080412</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (therapeutic use)</term>
<term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Basal Ganglia (drug effects)</term>
<term>Basal Ganglia (physiopathology)</term>
<term>Blood-Brain Barrier (drug effects)</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Cortical‐basal ganglionic degeneration</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Glycine</term>
<term>Glycine (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Milacemide</term>
<term>Movement Disorders (classification)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (physiopathology)</term>
<term>Myoclonus</term>
<term>Progressive supranuclear palsy</term>
<term>Stiff‐person syndrome</term>
<term>Striatonigral degeneration</term>
<term>Synaptic Transmission (drug effects)</term>
<term>Treatment</term>
<term>Videotape Recording</term>
<term>X‐linked dystonia</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Glycine</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term>
<term>Blood-Brain Barrier</term>
<term>Synaptic Transmission</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term>
<term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Videotape Recording</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term>
<term>Essai clinique</term>
<term>Homme</term>
<term>Milacémide</term>
<term>Myoclonie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X‐linked dystonia with parkinsonism, painful legs and moving toes, and stiff‐person syndrome. Milacemide was initiated at a dose of 2,400 mg/ day, orally, and increased gradually to a maximum of 4,800 mg/ day. No clear‐cut observable improvement occurred. There were no serious adverse effects.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Gordon, Mark Forrest" sort="Gordon, Mark Forrest" uniqKey="Gordon M" first="Mark Forrest" last="Gordon">Mark Forrest Gordon</name>
</region>
<name sortKey="Diaz Livo, Rolando" sort="Diaz Livo, Rolando" uniqKey="Diaz Livo R" first="Rolando" last="Diaz-Olivo">Rolando Diaz-Olivo</name>
<name sortKey="Fahn" sort="Fahn" uniqKey="Fahn" last="Fahn">Fahn</name>
<name sortKey="Hunt, Ann L" sort="Hunt, Ann L" uniqKey="Hunt A" first="Ann L." last="Hunt">Ann L. Hunt</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005D11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4D6408861423607BD4C2335834D9A2AD0E49505A
   |texte=   Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.